Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000295592 | SCV000330737 | pathogenic | not provided | 2018-05-01 | criteria provided, single submitter | clinical testing | This duplication of 56 nucleotides in ATM is denoted c.7010_7065dup56 at the cDNA level and p.Ile2356ValfsX2 (I2356VfsX2) at the protein level. The surrounding sequence is GAAT[dup56]ATCA. The duplication causes a frameshift which changes an Isoleucine to a Valine at codon 2356, and creates a premature stop codon at position 2 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. ATM c.7010_7065dup56 was reported in two siblings with pancreatic cancer from a kindred with pancreatic, colon, breast, and other cancer diagnoses (Barnes 2017). Based on the currently available information, we consider this duplication to be pathogenic. |
Ambry Genetics | RCV002365292 | SCV002666795 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-06-16 | criteria provided, single submitter | clinical testing | The c.7010_7065dup56 variant, located in coding exon 47 of the ATM gene, results from a duplication of GTCTGAGGGTTTGTGGCAACTGGTTAGCAGAAACGTGCTTAGAAAATCCTGCGGTC at nucleotide positions 7010 to 7065, causing a translational frameshift with a predicted alternate stop codon (p.I2356Vfs*2). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV002519063 | SCV003312405 | pathogenic | Ataxia-telangiectasia syndrome | 2022-12-31 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 280787). This variant has not been reported in the literature in individuals affected with ATM-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ile2356Valfs*2) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). |